OTCMKTS:CNBX CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis $0.0001 0.00 (-50.00%) As of 07/1/2026 12:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CNBX Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.0063Volume13.92 million shsAverage Volume32.88 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies. Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes. The company has assembled an intellectual property portfolio covering its lead compounds and key synthetic methods, positioning its programs for potential licensing or partnership opportunities that can support late-stage development and commercialization. CNBX Pharmaceuticals’ management team brings together experts in pharmaceutical chemistry, clinical development and regulatory affairs to guide its programs through critical R&D milestones. As a clinical-stage enterprise, CNBX remains focused on advancing its lead assets toward first-in-human trials and forging strategic alliances to accelerate the delivery of next-generation cannabinoid-based therapies for patients with significant unmet medical needs.AI Generated. May Contain Errors. Read More Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNBX Stock News HeadlinesCNBX Pharmaceuticals (OTC:CNBX) Stock Quotes, Forecast and News SummaryMarch 1, 2025 | benzinga.comCNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and DatesNovember 24, 2023 | benzinga.comWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% over 3-4 years, with some subscribers reporting gains of $141,000, $272,000, and even over $1 million. Now Karim sees a similar setup in what he calls the Energy Cube - a misunderstood technology backed by Bill Gates, Jeff Bezos, Google, and Microsoft. A major government milestone is expected this August that could force Wall Street to finally pay attention. Watch Karim's full presentation and learn why this overlooked opportunity may not stay overlooked for long.July 2 at 1:00 AM | Monument Traders Alliance (Ad)CNBX Pharmaceuticals Inc CNBXNovember 5, 2023 | morningstar.comMCNBX Historical DataOctober 9, 2023 | investing.comCNBX - CNBX Pharmaceuticals Inc.July 28, 2023 | finance.yahoo.comCNBX Acquires A Controlling Interest In Cancer Immunotherapy DeveloperNovember 8, 2022 | benzinga.comCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza BiopharmaNovember 8, 2022 | finance.yahoo.comSee More Headlines CNBX Stock Analysis - Frequently Asked Questions How have CNBX shares performed this year? CNBX Pharmaceuticals' stock was trading at $0.0004 on January 1st, 2026. Since then, CNBX shares have decreased by 75.0% and is now trading at $0.0001. When did CNBX Pharmaceuticals' stock split? CNBX Pharmaceuticals shares reverse split on the morning of Thursday, May 12th 2022.The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of CNBX Pharmaceuticals? Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CNBX Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNBX Pharmaceuticals investors own include Organigram Global (OGI), Green Thumb Industries (GTBIF), Canopy Growth (CGC), Curaleaf (CURLF), Kushco (KSHB) and Trulieve Cannabis (TCNNF). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryCannabis Current SymbolOTCMKTS:CNBX CIK1343009 Webwww.cannabics.com Phone(877) 424-2429FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:CNBX) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredGreatest Hedge Fund Manager of All Time: Get Out of StocksRay Dalio - who has made more money for clients than any hedge fund manager in history - is warning of a histo...TradeSmith | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNBX Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.